Ovation

Imagine a future where healthcare isn’t just reactive but deeply personalized — where every patient gets the right treatment at the right time based on a precise understanding of their biology. This is the future Ovation is building, and on this week’s Founded & Funded, Madrona Partner Chris Picardo dives into it all with Ovation CEO Curt Medeiros. From transforming underutilized clinical data into rich multiomics datasets to forging industry-leading partnerships with companies like Illumina, Curt shares how Ovation is shaping the future of precision medicine. He also opens up about the challenges of building a scalable, privacy-first platform, the lessons he brought with him from leading large healthcare businesses, and why collaboration and diversity are key to solving complex problems in healthcare. This episode isn’t just a deep dive into Ovation’s journey — it’s a masterclass for founders building innovative companies. Listen or watch wherever you get your podcasts: YouTube: https://bit.ly/3BOk1Wl Spotify: https://spoti.fi/4fGVGiX Apple: https://apple.co/4fGVG2r Amazon: https://amzn.to/40iLPf1 Madrona (Full Transcript): https://bit.ly/4a0cqR4

📢 Exciting News! Ovation.io is proud to announce a collaboration with Illumina to advance precision medicine. Together, we’ll leverage Illumina’s NGS technology and Ovation’s biobank of 1.6M + consented samples to accelerate the discovery of drug targets and biomarkers. This collaboration will focus on critical non-oncology indications like liver disease, chronic kidney disease, and GLP-1-treated patients, expanding genomic insights for better therapeutic outcomes. A huge step forward for genomics-driven research! 🧬 #Genomics #PrecisionMedicine #Collaboration #Innovation #DrugDiscovery #Ovation #Illumina

📢 Exciting News! Ovation.io is proud to announce a collaboration with Illumina to advance precision medicine. Together, we’ll leverage Illumina’s NGS technology and Ovation’s biobank of 1.6M + consented samples to accelerate the discovery of drug targets and biomarkers. This collaboration will focus on critical non-oncology indications like liver disease, chronic kidney disease, and GLP-1-treated patients, expanding genomic insights for better therapeutic outcomes. A huge step forward for genomics-driven research! 🧬 #Genomics #PrecisionMedicine #Collaboration #Innovation #DrugDiscovery #Ovation #Illumina

Here at Ovation, we often discuss how incorporating human genetic evidence into drug development doubles the probability of approval. This finding is based on seminal 2015 research published by Matthew Nelson and his coauthors in Nature Genetics. Earlier this month, these authors extended their research with a new study published in Nature (Nature Portfolio). The study revealed that the impact of genetic evidence is even stronger—increasing success rates by 2.6 times. In some therapeutic areas, the success rate can even quadruple!   In a recent press release, Nelson emphasized the value of these insights, stating, "These findings further demonstrate that genetic evidence is the most effective means to improve drug discovery and development success rates and R&D efficiency." As we honor #DNADay🧬, we celebrate not only the groundbreaking discoveries of the past but also the exciting future possibilities. This latest study underscores that we are far from fully tapping into the potential genetic evidence in advancing therapies to the clinic. Ovation is proud to advance this mission by generating genomic and other omics data that empower researchers to develop treatments that significantly impact human health. - New paper: https://lnkd.in/edsE4pXd - Earlier paper: https://lnkd.in/ejdC9tzt - Press release: https://lnkd.in/ecxZYQwe

At the recent 2nd Precision Medicine in IBD Summit, it was our honor to collaborate with DNAnexus in a session that explored the transformative power of leveraging high-value multiomics data alongside an advanced analysis platform to accelerate IBD drug discovery research. Couldn't attend the session? We've got you covered! Our latest blog captures the essential takeaways from the presentation, including the impactful work Ovation and DNAnexus are doing to help researchers use multiomics data to gain faster insights into IBD. Check out the event recap on our blog: https://lnkd.in/eZBNFJYt #precisionmedicine #IBDresearch #multiomics

It was an inspiring first day at the Precision Medicine in Inflammatory Bowel Disease Summit! We held an engaging session with our partner, DNAnexus, on the transformative power of high-value multiomics data combined with an advanced analysis platform. During our session, we showcased how integrating Ovation's comprehensive multiomics data with the advanced capabilities of the DNAnexus platform streamlines analysis and reduces time-to-insight for IBD research. Learn more about how Ovation and DNAnexus are working together to help life sciences companies drive innovation for IBD drug discovery and development by viewing our combined solution brief: https://lnkd.in/ecMUuBdJ

Join us at the Precision Medicine in IBD Summit in Boston next week! We're hosting a luncheon in collaboration with DNAnexus to discuss the role of multiomics data and advanced analytical platforms in propelling IBD drug discovery forward. Interested? Be part of our luncheon or set up a time to chat with us during the summit from March 19-21. Send a note to data_partnerships@ovation.io, and we'll arrange a time to connect. We're eager to collaborate and exchange ideas with the IBD precision medicine community!

Looking forward to our Luncheon Presentation with Ovation at The Precision Medicine in Inflammatory Bowel Disease Conference. Our discussion will focus on the impact of leveraging high-depth multiomics data and sophisticated analytical platforms to advance IBD drug discovery. Together, we'll showcase innovative solutions integrating comprehensive multiomics data and capabilities of an advanced precision health data cloud platform to enhance our understanding and treatment approaches. Interested in attending? Let us know! 

Are you heading to Boston for the upcoming Precision Medicine in Inflammatory Bowel Disease Summit? We're excited to host a luncheon presentation and discussion with DNAnexus! The session will focus on the impact of leveraging high-value multiomics data and sophisticated analysis platforms to advance IBD drug discovery. This is a great chance to connect with our team members, Martin Miller and Barry Wark, to explore how multiomics data solutions can help advance your IBD research. Let us know that you're interested in attending the luncheon or that you'd like to arrange a meeting during the summit (March 19-21) by sending a message to data_partnerships@ovation.io. We look forward to engaging with fellow innovators in the IBD precision medicine community. See you in Boston!

In case you missed it, Ovation started the year strong with significant achievements, reinforcing our commitment to advancing precision medicine through genomic and other omics data. Here's a quick overview of our key accomplishments this month: 🔬 Research at Crohn's & Colitis Congress 2024: Our team proudly presented research on leveraging diverse multiomics datasets to reveal insights into inflammatory bowel disease (IBD) biology. https://lnkd.in/e2YeiWW5 🤝 Strategic Collaboration with DNAnexus: We formally announced that we've teamed up with DNAnexus to help expedite biomarker and drug discovery by providing seamless access to Ovation's large-scale omics data on the advanced DNAnexus platform. https://lnkd.in/ew43C5Dv 🖥 Webinar with Amazon Web Services (AWS): Our recent session with AWS focused on using Amazon Redshift to explore Ovation's human omics data paired with rich clinical data. https://lnkd.in/greNSQGH We're excited about these developments and look forward to sharing more updates soon—stay tuned! #genomics #multiomics #drugdiscovery #awspartner #CCCongress24